SG
GSK icon

StoneX Group’s GSK GSK Stock Holding History

StoneX Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,197
Closed -$267K – 400
2023
Q4 		$267K Buy
+7,197
New +$258K 0.14% 210
2023
Q3 		– Sell
-6,251
Closed -$224K – 426
2023
Q2 		$224K Buy
+6,251
New +$224K 0.13% 263
2022
Q1 		– Sell
-4,578
Closed -$255K – 590
2021
Q4 		$255K Buy
+4,578
New +$238K 0.03% 452
2017
Q3 		– Sell
-30,446
Closed -$1.64M – 244
2017
Q2 		$1.64M Buy
30,446
+18,328
+151% +$977K 0.51% 51
2017
Q1 		$583K Sell
12,118
-156
-1% -$7.91K 1.3% 37
2016
Q4 		$591K Sell
12,274
-3,080
-20% -$152K 1.03% 48
2016
Q3 		$828K Buy
+15,354
New +$842K 1.85% 16

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

StoneX Group's GSK Position: Q1 2024 in Review

StoneX Group sold out of GSK (GSK) in Q1 2024, closing a stake of 7,197 shares — an estimated $267K sold.

StoneX Group first reported a position in GSK in Q3 2016 and held it in 7 quarters. The position peaked at $1.64M in Q2 2017. 910 funds tracked by Wall St. Rank hold GSK as of Q1 2024.

  • StoneX Group reported no remaining GSK position as of Q1 2024 after selling out during the quarter.
  • StoneX Group sold 7,197 GSK shares in Q1 2024, an estimated $267K.
  • StoneX Group first reported a position in GSK in Q3 2016 and held it in 7 quarters.
  • StoneX Group's GSK position peaked at $1.64M in Q2 2017.
  • 910 funds tracked by Wall St. Rank held GSK as of Q1 2024.

Based on StoneX Group's 13F filing for Q1 2024, filed 1 May 2024.